Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Anja Muskulus"'
Autor:
Daniela Wesch, Matthias Peipp, Andreas Humpe, J.G.J. van de Winkel, P. W. Parren, Dieter Kabelitz, Anja Muskulus, Renate Burger, Christian Kellner, Sebastian Lutz, Martin Gramatzki, Hans-Heinrich Oberg
Publikováno v:
Peipp, M, Wesch, D, Oberg, H H, Lutz, S, Muskulus, A, van de Winkel, J G J, Parren, P W H I, Burger, R, Humpe, A, Kabelitz, D, Gramatzki, M & Kellner, C 2017, ' CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells ', Scandinavian Journal of Immunology, vol. 86, no. 4, pp. 196-206 . https://doi.org/10.1111/sji.12581
Human γδ T cells are innate-like T cells which are able to kill a broad range of tumor cells and thus may have potential for cancer immunotherapy. The activating receptor natural killer group 2 member D (NKG2D) plays a key role in regulating immune
Autor:
Paul W. H. I. Parren, Matthias Peipp, B.E.C.G. de Goeij, Wim K. Bleeker, J. J. Lammerts van Bueren, Pia Glorius, Stefanie Derer, J.G.J. van de Winkel, Katja Klausz, Christian Kellner, Thomas Valerius, Matthias Staudinger, Anja Muskulus, Martin Gramatzki
Publikováno v:
Journal of immunological methods. 371(1-2)
Antibody-drug conjugates (ADC) represent promising agents for targeted cancer therapy. To allow rational selection of human antibodies with favorable characteristics for ADC development a screening tool was designed obviating the need of preparing in
Autor:
Paul W. H. I. Parren, Michael Dechant, Thomas Valerius, Jan G. J. van de Winkel, Matthias Staudinger, Patrick Van Berkel, Dalia Akramiene, Christian Kellner, Anja Muskulus, Martin Gramatzki, Pia Glorius, Georg H. Fey, Matthias Peipp, Sahar Mohseni Nodehi, Roland Repp
Publikováno v:
Journal of immunological methods. 373(1-2)
Protein- or glyco-engineering of antibody molecules can be used to enhance Fc-mediated effector functions. ScFv-Fc fusion proteins (scFv-Fc) represent interesting antibody derivatives due to their relatively simple design and increased tissue penetra
Autor:
Anja Muskulus, Matthias Peipp, Martin Gramatzki, Andreas Guenther, Roland Repp, Matthias Staudinger, Renate Burger
Publikováno v:
Blood. 112:3658-3658
Despite new treatment modalities, the clinical outcome of at least a subgroup of patients with multiple myeloma (MM) still needs improvement. Antibody-based targeted therapies are increasingly used for tumor therapy, and may represent interesting opt